-+ 0.00%
-+ 0.00%
-+ 0.00%

Reactor Clearance Could Be A Big Test For Oklo Stock (OKLO)

Simply Wall St·11/16/2026 14:12:06
Listen to the news
  • Oklo reported that the U.S. Department of Energy has cleared the final operations hold point for its Groves-1 isotope test reactor, allowing the facility to move into unrestricted research, testing, and training operations that directly support Aurora fast fission reactors and isotope production plans.
  • The Groves-1 facility now gives Oklo a full nuclear training and testing platform, including human factors data, control rod reliability work, and criticality benchmarks that can inform both Oklo’s own designs and potentially support performance improvements in the wider light water reactor fleet.
  • We will look at how Oklo’s investment narrative around long term power contracts and nuclear execution is reshaped by the operational clearance of Groves-1.

Scan beyond Oklo’s nuclear push and explore other potential beneficiaries of the same long-term energy buildout with our curated list of 17 nuclear energy infrastructure stocks.

Oklo Investment Narrative Recap

To own Oklo, you need to believe that its Aurora reactors and fuel recycling can turn long term power purchase agreements into recurring cash flows, as CE, an investor in the Simply Wall St Community, argues. The Groves-1 clearance adds real world operating data and a training venue, which supports that vision but does not change the absence of commercial plants or material revenue today.

In the short term, the key catalyst is progress on getting the first Aurora powerhouse built and operating. The biggest risk remains execution and regulatory slippage while losses stay heavy and revenue sits around US$3.1 million, especially with ongoing dilution and no clear path to profitability yet.

The most relevant follow-on update is Oklo’s third quarter 2026 result, which shows how much burn sits behind Groves-1 and the broader buildout. Management reported US$1.86 million in quarterly sales, a net loss of US$41.75 million and US$123.35 million of losses over nine months, against earlier capital raises of about US$2.3b.

Groves-1 therefore moves the operational story forward, while the financial profile still sits firmly in early stage mode. Investors now watch whether this new test bed and training platform can compress technical risk for Idaho and future Aurora projects before cash outflows and further equity raises dilute existing holders further.

CE values Oklo at US$80.55 a share using a narrative that assumes very large annual revenue expansion of about 10853% and a future profit margin of 11.7%, arguing that long term power contracts eventually turn Aurora output into steady earnings.

Uncover why Oklo's fair value indicates a 237% potential upside to its current price that may not last much longer.

NYSE:OKLO 1-Year Stock Price Chart
NYSE:OKLO 1-Year Stock Price Chart

Exploring Other Perspectives

You might see Groves-1 as a useful test bed, while the most optimistic analysts zoom in on isotope production as a key swing factor. Before this update, they were modelling revenue reaching about US$148.7 million and earnings of US$22.8 million by 2029. Those forecasts did not factor in today’s news, so their story could shift.

Explore 6 other Oklo fair value estimates, including one that suggests as much as 405% upside from the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking For More Investment Ideas Beyond Oklo?

If Groves-1 has put Oklo firmly on your radar, it can still pay to keep a wider watchlist. The Simply Wall St Screener lets you quickly scan for other opportunities that suit your approach, whether you care more about value, strength, or resilience.